BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27864651)

  • 1. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients.
    Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG
    Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
    Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
    Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
    Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
    Martins-Costa MC; Cunha LL; Lindsey SC; Camacho CP; Dotto RP; Furuzawa GK; Sousa MS; Kasamatsu TS; Kunii IS; Martins MM; Machado AL; Martins JR; Dias-da-Silva MR; Maciel RM
    Endocr Relat Cancer; 2016 Dec; 23(12):909-920. PubMed ID: 27807060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.
    González-Yebra B; Medrano ME; Mantilla A; Palma V; Colin C; Hernández DM; Tapia J; Dawson B; Salcedo M
    Endocr Pathol; 2003; 14(1):71-80. PubMed ID: 12746565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genotype-phenotype correlations in multiple endocrine neoplasia type 2].
    Zhang XW; Wang JY; Zhang YB; Wan HF; Zhang B; Yan DG; Liu WS; Xu ZG; Tang PZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jul; 51(7):538-41. PubMed ID: 27480304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
    Frank-Raue K; Raue F
    Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-specific progression of hereditary medullary thyroid cancer.
    Machens A; Lorenz K; Weber F; Dralle H
    Hum Mutat; 2018 Jun; 39(6):860-869. PubMed ID: 29656518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation.
    Chang JS; Chang CF; Yang WS; Chang TC
    Acta Cytol; 2011; 55(6):556-62. PubMed ID: 22156466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.
    Peppa M; Boutati E; Kamakari S; Pikounis V; Peros G; Panayiotides IG; Economopoulos T; Raptis SA; Hadjidakis D
    Eur J Endocrinol; 2008 Dec; 159(6):767-71. PubMed ID: 18805915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
    Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
    Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermal Hyperneury and Multiple Sclerotic Fibromas in Multiple Endocrine Neoplasia Type 2A Syndrome.
    Alegría-Landa V; Jo-Velasco M; Robledo M; Requena L
    JAMA Dermatol; 2017 Dec; 153(12):1298-1301. PubMed ID: 29049491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.